References

1. Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol. 1996; 80:389-393.

2. Sommer A, Tielsch JM, Katz J, et al. Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans: the Baltimore Eye Survey. Arch Ophthalmol. 1991;109:1090-1095.

3. Quigley HA, West SK, Rodriguez J, et al. The prevalence of glaucoma in a population-based study of Hispanic subjects: Proyecto VER. Arch Ophthalmol. 2001;119:1819-1826.

4. Iwase A, Suzuki Y, Araie M, et al. The prevalence of open angle glaucoma in Japanese: the Tajimi Study. Ophthalmology 2004;111:1641-1648.

5. Primary Open-Angle Glaucoma Preferred Practice Pattern. San Francisco, CA: American Academy of Ophthalmology; 2005. www.aao.org/education/guidelines/ppp/poag_ new.cfm.

6. Armaly MF, Krueger DE, Maunder L, et al. Biostatistical analysis of the Collaborative Glaucoma Study, I: summary report of the risk factors for glaucomatous visual-field defects. Arch Ophthalmol. 1980;98:2163-2171.

7. Tielsch JM, Sommer A, Katz J, et al. Racial variations in the prevalence of primary open-angle glaucoma: the Baltimore Eye Survey. JAMA. 1991;266:369-374.

8. Tielsch JM, Katz J, Sommer A, et al. Family history and the risk of primary open-angle glaucoma: the Baltimore Eye Survey. Arch Ophthalmol. 1994;112:69-73.

9. Gordon MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: Baseline factors that predict the onset of primary open angle glaucoma. Arch Ophthalmol. 2002; 120:714-20.

10. Gaasterland D, Tanishima T, Kuwabara T. Axoplasmic flow during chronic experimental glaucoma, I: light and electron microscopic studies of the monkey optic ner-vehead during development of glaucomatous cupping. Invest Ophthalmol Vis Sci. 1978;17:838-846.

11. Quigley HA, Addicks EM. Chronic experimental glaucoma in primates, II: effect of extended intraocular pressure elevation on optic nerve head and axonal transport. Invest Ophthalmol Vis Sci. 1980;19:137-152.

12. Cartwright MJ, Anderson DR. Correlation of asymmetric damage with asymmetric intraocular pressure in normal-tension glaucoma (low-tension glaucoma). Arch Ophthalmol. 1988;106:898-900.

13. Crichton A, Drance SM, Douglas GR, Schulzer M. Unequal intraocular pressure and its relation to asymmetric visual field defects in low-tension glaucoma. Ophthalmology. 1989;96:1312-1314.

14. Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Oph-thalmol. 1998;126:498-505.

15. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study. A randomized trial determines that topical ocular hypertensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002; 120:701-713.

Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression. Results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268-1279.

Shin DH, Bielik M, Hong YJ, et al. Reversal of glaucomatous optic disc cupping in adult patients. Arch Ophthalmol. 1989;107:1599-1603.

Marcic TS, Belyes DA, Katz B. Neuroprotection in glaucoma: a model for neuroprotection in optic neuropathies. Curr Opin Ophthalmol. 2003;14:353-356. Levin LA. Neuroprotection and regeneration in glaucoma. Ophthalmol Clin North Am. 2005;18:585-596.

Jay JL, Allan D. The benefit of early trabeculectomy versus conventional management in primary open angle glaucoma relative to severity of disease. Eye. 1989;3: 528-535.

Migdal C, Gregory W, Hitchings R. Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma. Ophthalmology. 1994; 101:1651-1657.

Lavin MJ, Wormald RP, Migdal CS, Hitchings RA. The influence of prior therapy on the success of trabeculectomy. Arch Ophthalmol. 1990;108:1543-1548. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT) and Glaucoma Laser Trial Follow-up Study, 7: results. Am J Ophthalmol. 1995;120:718-731. Damji KF, Shah KC, Rock WJ et al. Selective laser trabeculoplasty V argon laser tra-beculoplasty: a prospective randomized clinical trial. Br J Ophthalmol. 1999;83: 718-722.

Juzych MS, Chopra V, Banitt MR, et al. Comparison of long-term outcomes of argon laser trabeculoplasty in open-angle glaucoma. Ophthalmology. 2004; 111:1853-1859. Latina MA, Sibayan SA, Shin DH et al. Q-switched 532-nm ND:YAG laser trabecu-loplasty (selective laser trabeculoplasty): a multicenter, pilot clinical study. Ophthalmology. 1998;105:2082-2088.

Francis BA, Ianchulev T, Schofield JK, Minckler DS. Selective laser trabeculoplasty as a replacement for medical therapy in open-angle glaucoma. Am J Ophthalmol 2005; 140:524-525.

Song J, Lee PP, Epstein DL et al. High failure rate associated with 180 degrees selective laser trabeculoplasty. J Glaucoma. 2005;14:400-408.

Fluorouracil Filtering Surgery Study Group. Five-year follow-up of the Fluorouracil Filtering Surgery Study. Am J Ophthalmol. 1996;121:349-366. Singh K, Egbert PR, Byrd S, et al. Trabeculectomy with intraoperative 5-fluorouracil vs mitomycin C. Am J Ophthalmol. 1997;123:48-53.

Greenfield DS, Suner IJ, Miller MP, et al. Endophthalmitis after filtering surgery with mitomycin. Arch Ophthalmol. 1996;114:943-949.

Greenfield DS, Liebmann JM, Jee J, Ritch R. Late-onset bleb leaks after glaucoma filtering surgery. Arch Ophthalmol. 1998;116:443-447.

Ederer F, Gaasterland DA, Dally LG et al. The Advanced Glaucoma Intervention Study (AGIS): 13. Comparison of treatment outcomes within race: 10-year results. Ophthalmology. 2004;111:651-664.

AGIS Investigators. The Advanced Glaucoma Intervention Study: 8. Risk of cataract formation after trabeculectomy. Arch Ophthalmol. 2001;119:1771-1779. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130:429-440.

Nouri-Mahdavi K, Hoffman D, Coleman AL, et al. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology. 2004;111:1627-1635.

Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol. 1998;126: 487-497.

Drance S, Anderson DR, Schulzer M, et al. Risk factors for progression of visual field abnormalities in normal-tension glaucoma. Am J Ophthalmol. 2001;131:6997-6708.

Medeiros FA, Weinreb RN, Sample PA, et al. Validation of a predictive model to estimate the risk of conversion from ocular hypertension to glaucoma. Arch Oph-thalmol. 2005;123:1351-1360.

Leske MC, Heijl A, Hussien M, et al. Factors for glaucoma progression and the effect of treatment. Arch Ophthalmol. 2003;121:48-56.

Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001;108:1943-1953. Janz NK, Wren PA, Lichter PA, et al. Quality of life in newly diagnosed glaucoma patients. Collaborative Initial Glaucoma Treatment Study. Ophthalmology. 2001;108: 887-897.

European Glaucoma Prevention Study (EGPS) Group. Results of the European Glaucoma Prevention Study. Ophthalmology. 2005;112:366-375. Quigley HA. Letters to the Editor. European Glaucoma Prevention Study. Ophthalmology. 2005;112:1642-1643.

Grant WM, Burke JF Jr. Why do some people go blind from glaucoma? Ophthalmology. 1982;89:991-998.

Anderson DR. Glaucoma: the damage caused by pressure [XLVI Edward Jackson Memorial Lecture]. Am J Ophthalmol. 1989;108:485-495. Jampel HD. Target pressure in glaucoma therapy. J Glaucoma. 1997;6:133-138. Ashburn FS Jr, Goldberg I, Kass MA. Compliance with ocular therapy. Surv Ophthalmol. 1980;24:237-248.

Chung PY, Schuman TS, Netland PA, et al. Five-year results of a randomized, prospective clinical trial of diode vs argon laser trabeculoplasty for open-angle glaucoma. Am J Ophthalmol. 1998;126:185-190.

Lee AG, Anderson R, Kardon RH, et al. Presumed "sulfa allergy'' in patients with intracranial hypertension treated with acetazolamide or furosemide: cross-reactivity, myth or reality? Am J Ophthalmol. 2004;138:114-118.

Warwar RE, Bullock JD, Ballal D. Cystoid macular edema and anterior uveitis associated with latanoprost use: experience and incidence in a retrospective review of 94 patients. Ophthalmology. 1998;105:263-268.

Packer M, Fine IH, Hoffmann RS. Bilateral nongranulomatous anterior uveitis associated with bimatoprost. J Cataract Refract Surg. 2003;11:2242-2243. Kumarasamy M, Desai S. Anterior uveitis associated with travoprost. BMJ. 2004; 329(7459):205.

Faulkner WJ, Burk SE. Acute anterior uveitis and corneal edema associated with travoprost. Arch Ophthalmol. 2003;121:1054-1055.

Wand M, Gaudio AR. Cystoid macular edema associated with ocular hypotensive lipids. Am J Ophthalmol. 2002;133:393-397.

Hedman K, Larsson LI. The effect of latanoprost compared with timolol in African-American, Asian, Caucasian and Mexican open-angle glaucoma or ocular hypertensive patients. Surv Ophthalmol. 2002;47(suppl 1):S77-S89.

Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132:472-484.

Brandt JD, VanDenburgh AM, Chen K, et al. Comparison of once or twice daily bi-matoprost with twice-daily timolol in patients with elevated IOP: a 3-month clinical trial. Ophthalmology. 2001;108:1023-1031.

Noecker RS, Dirks MS, Choplin N, et al. Comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003;135:688-703. Parrish RK, Palmberg P, Sheu WP, et al. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure. a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003;135:688-703. Asrani S, Zeimer R, Wilensky J, et al. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma. 2000;9:134-142. Larsson LI, Mishima HK, Takamatsu M, et al. The effect of latanoprost on circadian intraocular pressure. Surv Ophthalmol. 2002;47(suppl 1):S90-S96. Orzalesi N, Rossetti L, Bottoli A, et al. Comparison of the effects of latanoprost, travoprost and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Ophthalmology. 2006;113:239-246. Schumer RA, Camras CB, Mandahl AK. Putative side effects of prostaglandin analogs. Surv Ophthalmol. 2002;47(suppl 1):S219-s230.

Wand M, Ritch R, Isbey EK Jr, et al. Latanoprost and periocular skin color changes. Arch Ophthalmol. 2001;119:614-615.

Johnstone MA, Albert DM. Prostaglandin-induced hair growth. Surv Ophthalmol. 2002;47(suppl 1):S185-S202.

Gandolfi SA, Cimino L. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost. Ophthalmology. 2003;110:609-614.

Zimmerman TJ, Kaufman HE. Timolol: a beta-adrenergic blocking agent for the treatment of glaucoma. Arch Ophthalmol. 1977;95:601-604.

Freedman SF, Freedman NJ, Shields MB, et al. Effects of ocular carteolol and timolol on plasma high-density lipoprotein cholesterol level. Am J Ophthalmol. 1993;116: 600-611.

Allen RC, Epstein DL. Additive effect of betaxolol and epinephrine in primary open angle glaucoma. Arch Ophthalmol. 1986;104:1178-1184.

Harris LS, Greenstein SH, Bloom AF. Respiratory difficulties with betaxolol. Am J Ophthalmol. 1986;102:274-275.

Katz LJ. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine Study Group. Am J Ophthalmol. 1999; 127:20-26.

Adamsons IA, Polis A, Ostrov CS, Boyle JE. Two-year safety study of dorzolamide as monotherapy and with timolol and pilocarpine. Dorzolamide Safety Study Group. J Glaucoma. 1998;7:395-401.

Silver LH. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brin-zolamide Primary Therapy Study Group. Am J Ophthalmol. 1998;126:400-408.

75. Zimmerman TJ, Kooner KS, Kandarakis AS, Ziegler LP. Improving the therapeutic index of topically applied ocular drugs. Arch Ophthalmol. 1984;102:551-553.

76. Realini T, Fechtner R, Atreides SP, Gollance S. The uniocular drug trial and second-eye response to glaucoma medications. Ophthalmology. 2004;111:421-426.

77. Sit AJ, Liu JHK, Weinreb RN. Asymmetry of right versus left intraocular pressures over 24 hours in glaucoma patients. Ophthalmology. 2006;113:425-430.

78. Zimmerman TJ, Kass MA, Yablonski ME, Becker B. Timolol maleate: efficacy and safety. Arch Ophthalmol. 1979;97:656-658.

79. Primary Open-Angle Glaucoma Suspect Preferred Practice Pattern. San Francisco, CA: American Academy of Ophthalmology; 2005. www.aao.org/education/guidelines/ ppp/poags_new.cfm

Reducing Blood Pressure Naturally

Reducing Blood Pressure Naturally

Do You Suffer From High Blood Pressure? Do You Feel Like This Silent Killer Might Be Stalking You? Have you been diagnosed or pre-hypertension and hypertension? Then JOIN THE CROWD Nearly 1 in 3 adults in the United States suffer from High Blood Pressure and only 1 in 3 adults are actually aware that they have it.

Get My Free Ebook


Post a comment